dpp4 and glp 1 combination Inhibitors vs GLP-1 Agonists | June 2021 | Clinical Corner Frontiers | Physiology and Pharmacology

Semaglutide for Adults Living With Obesity

MDPI Rebalancing the Gut: GlucagonLike Peptide1 Agonists as a Strategy for Obesity and Metabolic Health Singh, K., Aulakh, S

Preliminary investigations into GLP-1RAs for neurodegenerative conditions, such as Alzheimers and Parkinsons diseases, as well as addiction disorders, suggest novel therapeutic avenues

Other clinically relevant GI complications include cholelithiasis, which occurred about 50 % more often, and gastroesophageal reflux disease (GERD), which occurred roughly twice as often, in patients receiving GLP-1 therapies compared with placebo [33]

Selecting that youre in an energy deficit reduces calculated BMR by 5%

B., Zekavat, S